EMBLA MEDICAL HF. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.7 DKK | +1.71% |
|
-1.33% | +8.20% |
| Apr. 23 | Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024 | |
| Apr. 23 | Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.20% | 1.79B | B+ | ||
| +2.36% | 24.07B | B | ||
| -5.87% | 16.75B | A | ||
| +8.42% | 13.7B | B | ||
| -15.85% | 2.06B | - | ||
| +40.94% | 1.73B | D- | ||
| +11.40% | 589M | - | ||
| 0.00% | 400M | - | - | |
| +29.45% | 135M | - | ||
| +27.49% | 93.49M | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EMBLA Stock
- Ratings Embla Medical hf.
